¡GoConqr estrena diseño! Cuéntanos qué te parece.

Regístrate gratis

Test

NE10 Other neurological disorders

Usuario eliminado 16 preguntas Actualizado el 11 oct 2019

Hacer el test

Este test tiene tipos de pregunta que se abren en el reproductor de siempre.

Preguntas del test (16)

  1. 1By the end of this lecture you will be able to:
    1. Describe the pathophysiology of motor neurone disease and multiple sclerosis
    2. Describe available treatments for these disorders
    • Mechanisms of action
    • Main unwanted effects

    [blank_start]OK[blank_end]
    1. AOK
  2. 2Motor neurone disease is [blank_start]progressive degeneration[blank_end] of motor neurons. The most affected group is [blank_start]middle aged males[blank_end].
    Motor neurons - Upper ones originate in brain, lower ones originate in spinal cord. MND affects [blank_start]both[blank_end] upper and lower. Also know as:
    • [blank_start]Lou Gehrig's[blank_end] Disease
    • Charcot's Disease (in Europe).
    • Amyotrophic Lateral [blank_start]Sclerosis[blank_end] (in US)
    1. Aprogressive degeneration
    2. Bmiddle aged males
    3. Cboth
    4. DSclerosis
    5. ELou Gehrig's
  3. 3Which of these is NOT a presentation of MND?
    1. AStumbling
    2. BDropping, difficulty holding things
    3. CHoarse voice/slurred speech
    4. DMuscle cramps
    5. EDysphagia
    6. FFatigue
    7. GBehavioural/emotional changes
    8. HSevere cognitive difficulties
  4. 4What causes MND?
    Most cases [blank_start]sporadic[blank_end]...
    • [blank_start]Viral[blank_end] infection
    • [blank_start]Immune[blank_end] mediated damage
    • Premature motor neuron [blank_start]aging[blank_end]
    • Loss of [blank_start]growth factors[blank_end]
    [blank_start]5-10[blank_end]% hereditary ([blank_start]SOD[blank_end] mutation).

    Pathophysiology?
    • TDP-43 [blank_start]RNA splicing[blank_end] dysfunction
    • Excessive [blank_start]glutamate R[blank_end] activation
    • Intracellular [blank_start]Ca2+ overload[blank_end]
    • Mitochondrial damage
    • [blank_start]Excitotoxic[blank_end] cell death
    • Oxidative stress ([blank_start]free radicals[blank_end])
    1. Asporadic
    2. BViral
    3. CImmune
    4. Daging
    5. Egrowth factors
    6. F5-10
    7. GSOD
    8. Hglutamate R
    9. ICa2+ overload
    10. JExcitotoxic
    11. Kfree radicals
    12. LRNA splicing
  5. 5Tx for motor neurone disease:
    1. Riluzole
    Slows progression, prolongs median survival time by [blank_start]2-3 months[blank_end]
    Multiple effects on [blank_start]glutamate[blank_end] neurotransmission.
    Presynapic: inhibits [blank_start]release[blank_end] - inhibits [blank_start]voltage gated Na+[blank_end] channels
    Postsynaptic: prevents [blank_start]action[blank_end] - non competitive [blank_start]blockade of NMDA[blank_end] Rreceptors
    Contraindicated: hepatic impairment
    Caution: [blank_start]neutropenia[blank_end] (fever, sore-throat, malaise)

    2. Endaravone (not available in NZ). First FDA approved MND therapy in [blank_start]22[blank_end] years. Free [blank_start]radical[blank_end] scavenger.
    1. A2-3 months
    2. Bglutamate
    3. Cvoltage gated Na+
    4. Drelease
    5. Eaction
    6. Fblockade of NMDA
    7. Gneutropenia
    8. H22
    9. Iradical
  6. 6Which of these is not a common unwanted effect of riluzole?
    1. ANausea and vomiting
    2. BLethargy
    3. CDizziness
    4. DDiarrhoea
  7. 7Multiple Sclerosis is an [blank_start]autoimmune[blank_end] disorder that affects nerve [blank_start]conduction[blank_end]. There are multiple areas of [blank_start]scarring[blank_end] in the brain, and spinal cord. Inflammation causes relapse. [blank_start]Demyelination and axon damage[blank_end] cause:
    Optic neuritis, weakness, spasticity, ataxia, [blank_start]bladder and bowel[blank_end] dysfunction.

    Epidemiology:
    - Affects 1 in 1000
    - [blank_start]Young[blank_end] adults (average age 37 years old)
    - [blank_start]Women[blank_end] three times more than men
    • [blank_start]Caucasians[blank_end]
    • People in [blank_start]cooler[blank_end] climates
    1. Aautoimmune
    2. Bconduction
    3. Cscarring
    4. DDemyelination and axon damage
    5. Ebladder and bowel
    6. FYoung
    7. GWomen
    8. HCaucasians
    9. Icooler
  8. 8Pathology of MS:
    Trigger = [blank_start]peripheral[blank_end] immune response. Primed [blank_start]T and B[blank_end] lymphocytes cross [blank_start]BBB[blank_end]. Upregulation of [blank_start]integrins[blank_end] causes [blank_start]adhesion[blank_end],

    Inflammation -
    [blank_start]Th1 lymphocytic[blank_end] autoimmune response involving INF-g, IL-17, TNF-b.

    [blank_start]B[blank_end] cell mediated [blank_start]antibodies[blank_end] - [blank_start]Initiate[blank_end] myelin destruction

    [blank_start]Macrophages[blank_end] -
    Destroy myelin [blank_start]sheath[blank_end], damage [blank_start]oligo[blank_end]dendrocytes. Demyelination leads to [blank_start]axon[blank_end] damage
    1. Aperipheral
    2. BT and B
    3. CBBB
    4. Dintegrins
    5. Eadhesion
    6. FTh1 lymphocytic
    7. GB
    8. Hantibodies
    9. IInitiate
    10. JMacrophages
    11. Ksheath
    12. Loligo
    13. Maxon
  9. 9Drug treatment for MS:
    Reduction of symptoms.
    15% of patients have [blank_start]primary[blank_end] progressive MS, 85% [blank_start]relapsing- remitting[blank_end] MS ([blank_start]secondary[blank_end] progressive MS).
    • Modulating immune response early reduces [blank_start]disability[blank_end]
    1. Aprimary
    2. Brelapsing- remitting
    3. Csecondary
    4. Ddisability
  10. 10Fingolimob
    • Oral [blank_start]prodrug[blank_end] (reversible [blank_start]phosphorylation[blank_end])
    • Agonist of [blank_start]sphingosine-1-phosphate[blank_end] R
    • Then internalisation prevents [blank_start]lymphocyte[blank_end] egress, reduced [blank_start]migration[blank_end] to lesions
    Immunomodulator - [blank_start]infections[blank_end] risk
    UEs: Headache, migraine, [blank_start]dizziness, paraesthesia, depression[blank_end]
    Caution: patients with [blank_start]CV[blank_end] risk – transient bradycardia, heart block.
    1. Aprodrug
    2. Bphosphorylation
    3. Csphingosine-1-phosphate
    4. Dlymphocyte
    5. Emigration
    6. Finfections
    7. Gdizziness, paraesthesia, depression
    8. HCV

Información

Descripción
El usuario ha eliminado su información de asignaturas Test sobre NE10 Other neurological disorders, creado por Usuario eliminado el 11/10/2019.
Autor
Usuario eliminado
Idioma
English
Visitas
58
Historial
Creado el 11 oct 2019 · actualizado el 11 oct 2019
Valoración
Aún sin valoraciones
Valora este test
Valora este test

Escríbenos

¿Sobre qué es tu mensaje?

¿Qué te parece el nuevo diseño?

¿Te gusta?